Skip to content

Study · Animal study (in vivo) · rat · 2007

3 results

Effect of pancragen on blood glucose level, capillary permeability and adhesion in rats with experimental diabetes mellitus.

Khavinson VKh, Gavrisheva NA, Malinin VV, Chefu SG, Trofimov EL

Bulletin of experimental biology and medicine1 Oct 2007Cited by 3 (Europe PMC)

PMID18642713 (opens in a new tab)DOI10.1007/s10517-007-0377-3 (opens in a new tab)PepBankPUB-18642713
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic Wistar rats, oral pancragen produced a pronounced hypoglycemic effect during treatment.

    In plain wordsIn rats with diabetes, oral pancragen lowered blood glucose during treatment.

    Peptide
    Pancragen (KEDW)
    Outcome
    DecreaseBlood glucose
    Study

    ratn: not reported in source

    Wistar rats with streptozotocin-induced diabetes mellitus
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · oralAs given in this study (rat).

    Source sentences

    Summary
    Oral pancragen produced a pronounced hypoglycemic effect during treatment.
    1 context sentence
    Summary · context
    The effects of tetrapeptide pancragen (Lys-Glu-Asp-Trp-NH2) on blood glucose level and permeability and adhesion of mesenteric capillaries were studied in Wistar rats with experimental streptozotocin-induced diabetes mellitus.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic Wistar rats, intramuscular pancragen normalized mesenteric capillary endothelial adhesion.

    In plain wordsIn rats with diabetes, intramuscular pancragen normalized adhesion in mesenteric capillary endothelium.

    Peptide
    Pancragen (KEDW)
    Outcome
    Direction not reportedMesenteric capillary endothelial adhesion
    Study

    ratn: not reported in source

    Wistar rats with streptozotocin-induced diabetes mellitus
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated · intramuscularAs given in this study (rat).

    Source sentences

    Summary
    Intramuscular pancragen normalized the adhesion of mesenteric capillary endothelium, but did not modify capillary permeability.
    1 context sentence
    Summary · context
    The effects of tetrapeptide pancragen (Lys-Glu-Asp-Trp-NH2) on blood glucose level and permeability and adhesion of mesenteric capillaries were studied in Wistar rats with experimental streptozotocin-induced diabetes mellitus.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic Wistar rats, intramuscular pancragen did not modify capillary permeability.

    In plain wordsIn rats with diabetes, intramuscular pancragen did not change capillary permeability.

    Peptide
    Pancragen (KEDW)
    Outcome
    No significant changeCapillary permeability
    Study

    ratn: not reported in source

    Wistar rats with streptozotocin-induced diabetes mellitus
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated · intramuscularAs given in this study (rat).

    Source sentences

    Summary
    Intramuscular pancragen normalized the adhesion of mesenteric capillary endothelium, but did not modify capillary permeability.
    1 context sentence
    Summary · context
    The effects of tetrapeptide pancragen (Lys-Glu-Asp-Trp-NH2) on blood glucose level and permeability and adhesion of mesenteric capillaries were studied in Wistar rats with experimental streptozotocin-induced diabetes mellitus.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 17:05 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.